Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Targeted therapies are increasingly used in cancer treatment.
• These therapies can lead to significant gastrointestinal (GI) toxicities and laboratory abnormalities.
• Effective management is essential to maintain treatment adherence and patient quality of life.

Purpose of the Study:

• To identify common GI toxicities and laboratory abnormalities associated with targeted therapies.
• To outline necessary assessment and management strategies for these adverse events.
• To emphasize the role of oncology nurses in managing these side effects.

Main Methods:

• Review of peer-reviewed articles.
• Consultation of national guidelines for oncology practice.

Main Results:

• Diarrhea and mucositis are common GI toxicities.
• Laboratory abnormalities are frequently observed.
• Targeted agents are often associated with these adverse events.

Conclusions:

• Skilled assessment and early intervention are vital for managing targeted therapy toxicities.
• Proactive management prevents severe complications and treatment delays.
• Oncology nurses play a key role in patient assessment, education, and evidence-based recommendations.